Merck: mixed results in esophageal adenocarcinoma
(CercleFinance.com) - Merck announces that the phase 3 trial evaluating the combination of Keytruda (pembrolizumab) and Lenvima (lenvatinib) with chemotherapy for the first-line treatment of patients with HER2-negative advanced gastroesophageal adenocarcinoma showed a significant improvement in progression-free survival (PFS) and objective response rate (ORR).
NB: pmt flat.
However, the trial failed to meet its other primary endpoint - that of overall survival (OS).
Treatment safety was consistent with previous studies. Full results will be presented at a future medical congress.
Copyright (c) 2025 CercleFinance.com. All rights reserved.
NB: pmt flat.
However, the trial failed to meet its other primary endpoint - that of overall survival (OS).
Treatment safety was consistent with previous studies. Full results will be presented at a future medical congress.
Copyright (c) 2025 CercleFinance.com. All rights reserved.